Search

Roots of innovation: From science fairs to the leading edge of precision genetic medicine
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
Treatment Access
Sarepta Therapeutics anuncia la convocatoria de solicitudes para la 8ª edición anual de Route 79, el Programa de Becas de Duchenne
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Corporate Responsibility
Our Products & Pipeline